E. Van Cutsem

Publications859
h-index147
Citations98,111
Highly Influential Citations3,561
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • J. Tabernero
  • 1,116 Publications • 57,227 Citations
  • D. Cunningham
  • 1,339 Publications • 87,366 Citations
  • T. André
  • 658 Publications • 35,718 Citations
  • E. Cutsem
  • 687 Publications • 21,330 Citations
  • Publications
  • Influence
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
TLDR
In patients with metastatic pancreatic adenocarcinoma, nab-paclitaxel plus gemcitabine significantly improved overall survival, progression-free survival, and response rate, but rates of peripheral neuropathy and myelosuppression were increased.
View on PubMed
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
TLDR
Cetuximab has clinically significant activity when given alone or in combination with irinotecan in patients with ir inotecans-refractory colorectal cancer.
View on PubMed
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
TLDR
Continuous daily administration of sunitinib at a dose of 37.5 mg improved progression-free survival, overall survival, and the objective response rate as compared with placebo among patients with advanced pancreatic neuroendocrine tumors.
View on PubMed
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
View on PubMed
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
TLDR
Adding docetaxel to CF significantly improved TTP, survival, and response rate in gastric cancer patients, but resulted in some increase in toxicity.
View on PubMed
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
TLDR
First-line treatment with cetuximab plus FOLFIRI, as compared with F OLFIRI alone, reduced the risk of progression of metastatic colorectal cancer and was limited to patients with KRAS wild-type tumors.
View on PubMed
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
TLDR
Panitumumab significantly improved PFS with manageable toxicity in patients with chemorefractory colorectal cancer and was well tolerated.
View on PubMed
Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors
TLDR
Treatment with lutetium‐177 (177Lu)–Dotatate resulted in markedly longer progression‐free survival and a significantly higher response rate than high‐dose octreotide LAR among patients with advanced midgut neuroendocrine tumors.
View on Wolters Kluwer
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
TLDR
These ESMO consensus guidelines have been developed based on the current available evidence to provide a series of evidence-based recommendations to assist in the treatment and management of patients with mCRC in this rapidly evolving treatment setting.
View on PubMed
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
View on Elsevier
...
...